Drug intelligence / Profile preview

Zhike Baidu powder

Development stage: Unknown
Lead developer: Guang'anmen Hospital
Administration: Oral

Overview

Zhike Baidu powder is a traditional Chinese medicine (TCM) oral formulation developed by Guang'anmen Hospital of the China Academy of Chinese Medical Sciences. It is specifically designed for the treatment of cough and other symptoms associated with adult upper respiratory tract infections (URTI), particularly those occurring during the winter and spring seasons. The formulation is part of the SMART clinical trial (ChiCTR2400080482), which evaluates its efficacy in adults with URTI-related cough in comparison to montelukast sodium and other TCM therapies. As a 'Baidu' (toxin-resolving) and 'Zhike' (cough-stopping) preparation, it likely functions through anti-inflammatory and antitussive properties derived from its constituent herbal ingredients.

Other names: Zhike Baidu San

Beyond the preview

Go deeper on Zhike Baidu powder.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zhike Baidu powder.

Explore the full profile